The Food and Drug Administration last night announced that its Vaccines and Related Biological Products Advisory Committee will convene Feb. 26 to discuss the emergency use authorization application by Johnson & Johnson and Janssen Biotech, Inc. for its investigational single-dose COVID-19 vaccine candidate.

The Johnson & Johnson candidate is the third to seek an EUA from the agency; the application follows topline efficacy and safety data culled from a phase 3 trial that showed a 72% effectiveness in the U.S. for preventing moderate-to-severe COVID-19.

Related News Articles

Headline
The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee today by a unanimous vote recommended that the FDA issue an…
Headline
The Centers for Disease Control and Prevention today revealed the comparative effectiveness of the three Food and Drug Administration-authorized COVID-19…
Headline
The Department of Health and Human Services’ Assistant Secretary for Preparedness and Response this week announced a major change in the distribution of…
Headline
The AHA has received a $1 million grant from the Centers for Disease Control and Prevention to continue for one year its efforts to encourage COVID-19…
Headline
A pair of peer-reviewed studies published in the New England Journal of Medicine are affirming the safety and effectiveness of Pfizer’s COVID-19 vaccine, first…
Headline
The Food and Drug Administration yesterday released an updated enforcement policy related to face masks, barrier face coverings, face shields,…